AAP
DERM icon

Arax Advisory Partners’s Journey Medical DERM Stock Holding History

Arax Advisory Partners’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$928 Buy
+131
New +$748 ﹤0.01% 4942
2025
Q4 		– Sell
-46
Closed -$327 – 4191
2025
Q3 		$327 Buy
+46
New +$334 ﹤0.01% 3408

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Arax Advisory Partners's DERM Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Journey Medical (DERM) in Q2 2026: 131 shares worth $928. The stake represents ﹤0.01% of the portfolio and ranks #4942 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in DERM as recently as Q3 2025.

Arax Advisory Partners first reported a position in DERM in Q3 2025 and has held it in 2 quarters since. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

  • Arax Advisory Partners held 131 shares of Journey Medical worth $928 as of Q2 2026.
  • Journey Medical was a new Arax Advisory Partners position in Q2 2026.
  • Journey Medical made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4942 holding.
  • Arax Advisory Partners first reported a position in Journey Medical in Q3 2025 and has held it in 2 quarters since.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.